This article was originally published in The Gray Sheet
Executive SummaryFirm's bladder cancer detection test is sensitive enough to allow urologists to reserve the use of rigid cystoscopy only for patients whose urinary nuclear matrix protein levels are found to be higher than six U/ml with the assay, according to a study of 105 bladder cancer patients by Alberto Del Nero, et al., published in the February edition of the journal European Urology. Using a cutoff of six U/ml, the test demonstrated a sensitivity of 92% (69/75) overall, compared to 50.6% (38/75) for Bion Diagnostics Sciences' BTA stat test and 46.6% (35/75) with urinary cytology
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.